A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma. - Wikidata - awgldk - TriplyDB

A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

http://www.wikidata.org/entity/Q37365825

about

Combined quantification of paclitaxel, docetaxel and ritonavir in human feces and urine using LC-MS/MS.Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.Development and validation of a UPLC-MS/MS method for the simultaneous determination of paritaprevir and ritonavir in rat liver Determination of intracellular unbound concentrations and subcellular localization of drugs in rat sandwich-cultured hepatocytes compared with liver tissue.A critical review of properties of darunavir and analytical methods for its determination.Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics.Characterization of the Oxidative Degradation Product of Darunavir by LC-MS/MS.UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues Stability-indicating HPLC method for the determination of darunavir ethanolate.Direct injection HILIC-MS/MS analysis of darunavir in rat plasma applying supported liquid extraction.Validation of simultaneous quantitative method of HIV protease inhibitors atazanavir, darunavir and ritonavir in human plasma by UPLC-MS/MS.Separation, Identification and Characterisation of Acidic Degradation of Ritonavir Under ICH Recommended Stress Condition by HPTLC, MS/TOF

P2860

Q31136016-D1AE3706-4675-45E5-AD8B-4E0562BA4BE2 Q33633139-559679E9-8E73-48CE-BFC9-F908749B6808 Q34432062-F5A9908D-B19E-4873-B903-1B9B5C5EDAB5 Q34737260-CB13765B-CF8F-4539-86A5-1B8E6A631E4D Q36279339-CC7B5141-B579-4F7B-AA16-5A73299300B7 Q37046055-33B6C582-0484-42D6-8107-1680D34219B5 Q37251993-E141CDE5-F1F6-4043-AC42-BFF78C15FEEB Q38267642-5F6FABA6-EB33-4AAF-81EB-C64D3CB00AC0 Q41218781-6D80B4A6-D49C-495E-9F91-4C9B3057D496 Q41917411-386F766E-7809-44E7-86AA-1654E5C10595 Q42844098-4B30EF0B-D17B-49C5-B038-1E1130BF852E Q46826514-4E664939-134C-4D70-9B3A-3FAB39A9E04A Q50091565-134A40C1-A34E-4A58-B5C7-D7EDB8CC89C9 Q51848081-E7C819DC-96D7-49A3-A0BF-B4B43516BFC6 Q58160014-44368E14-1FEB-4888-B3CD-A18DE515F9C2

P2860

A novel LC-ESI-MS method for the simultaneous determination of etravirine, darunavir and ritonavir in human blood plasma.

http://www.wikidata.org/entity/Q37365825

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 09 June 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@en

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@nl

type

label

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@en

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@nl

prefLabel

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@en

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@nl

P1433

Q37365825-09096C2B-9274-461F-80A1-2B3852D1F803

P1476

Q37365825-F879C6E1-5286-4123-8AE4-DA2602EA1739

P2093

Q37365825-160A1647-3FF4-4343-9FCA-15195D3B1F95

Q37365825-20DC3E53-931B-47D6-9246-712F2CD70556

Q37365825-A543979E-62C2-4383-8C6D-F58C2A204067

Q37365825-CE3F4930-C477-4A5C-A631-FBB9C664FE1F

P2860

Q37365825-1B063B3E-85AE-4EA2-AE2E-052356725CEC

Q37365825-1F06182C-8025-4523-9D35-B720983AA421

Q37365825-21E8F9CA-6EE8-4A1F-9B68-CC669D31E772

Q37365825-277D4823-58E1-442A-AF4C-0A1100F6B0FE

Q37365825-3F19C625-12FC-4E9A-BFCB-D4D783EF6473

Q37365825-4203AE84-1E10-4E86-991B-6F0438769B24

Q37365825-6E4C6109-A19A-4DE8-B05B-76B567688EE7

Q37365825-7B793F54-0D09-40EB-AE3D-F798EECC9E10

Q37365825-BF075314-A542-4AB3-BE06-42E47BC9C98F

Q37365825-C2C71827-00BB-40AC-BC56-226BE888467B

P304

Q37365825-C31F1E3B-0C99-4593-888F-2ABDE2302D49

P31

Q37365825-26EE1A2E-3959-4FA8-92A5-045C2B6076DD

P356

Q37365825-82A51D8A-8845-40A8-BA7C-0D84887B92C8

P407

Q37365825-EBC50033-4BCA-45ED-862F-8BD192390954

P433

Q37365825-6BBBF855-4AF3-4403-9A53-3AF084F20BEE

P478

Q37365825-69610988-50F4-415A-9622-288B27287457

P577

Q37365825-8EA09D88-AD38-45CB-B669-82B897F4A96B

P5875

Q37365825-5A1724AB-B570-413C-94C1-223706E06EB1

P698

Q37365825-DCADE643-F1A2-40C0-8B30-156C6538D302

P932

Q37365825-449432DC-4012-4619-A383-F018A9C851C8

P356

J.TALANTA.2009.06.005

P1433

P1476

A novel LC-ESI-MS method for t ...... tonavir in human blood plasma.

@en

P2093

Angela D M Kashuba

http://www.w3.org/2001/XMLSchema#string

Naser L Rezk

http://www.w3.org/2001/XMLSchema#string

Nicole R White

http://www.w3.org/2001/XMLSchema#string

Steven H Jennings

http://www.w3.org/2001/XMLSchema#string

P2860

Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories.

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Simple and rapid quantification of the non-nucleoside reverse transcriptase inhibitors nevirapine, delavirdine, and efavirenz in human blood plasma using high-performance liquid chromatography with ultraviolet absorbance detection.

Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals.

P304

1372-1378

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.TALANTA.2009.06.005

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

79

http://www.w3.org/2001/XMLSchema#string

P577

2009-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26698404

http://www.w3.org/2001/XMLSchema#string

P698

19635373

http://www.w3.org/2001/XMLSchema#string

P932

2753357

http://www.w3.org/2001/XMLSchema#string